Jeffrey S. Grand Joins Bernstein Liebhard LLP
Bernstein Liebhard LLP is pleased to announce that Jeffrey S. Grand joined the firm as a partner on May 2, 2011. Mr. Grand will be joining the Mass Tort practice area, where he will focus on pharmaceutical and mass tort litigation. Mr. Grand joins the firm with extensive experience in these areas, having actively litigated high-profile cases involving prescription drugs including Vioxx, Fosamax and Yaz. He has supervised the day-to-day management of complex, multi-party mass tort litigation in state and federal courts and multi-district litigation throughout the United States, and has served on discovery and administrative committees in these litigations. He has served as a member of the trial teams that obtained a $47.5 million verdict for Vioxx-related cardiovascular injury in Humeston v. Merck & Co., in New Jersey Superior Court in 2007, and several plaintiff victories in the Chinese-Manufactured Drywall Products Liability Litigation in the United States District Court, Eastern District of Louisiana. He also has extensive experience in the area of electronic discovery, most recently having served as a co-chair for electronic discovery in the Oil Spill by the Oil Rig “Deepwater Horizon” in the Gulf of Mexico, on April 20, 2010 Litigation, also in the Eastern District of Louisiana. Prior to joining Bernstein Liebhard, Mr. Grand was a partner at Seeger Weiss LLP. He is a 2002 graduate of Benjamin N. Cardozo School of Law.
With the addition of Mr. Grand to the firm’s Mass Tort team, Bernstein Liebhard LLP continues to expand this practice area. In this area, the firm represents clients who have been injured by dangerous drugs, defective medical devices, dangerous products and toxic substances, and has successfully represented consumers against large multi-national corporations, medical device companies, and pharmaceutical companies. Currently, the firm is litigating cases involving the recently recalled DePuy ASR hip replacement devices. The firm is also working on cases concerning atypical femur fractures resulting from long term use of bisphosphonates such as Fosamax, and is also investigating cases concerning denture cream, Accutane, Yasmin, transvaginal mesh, Topamax and SSRI birth defects.